CareCost Vials
1 × 1,800 mg
1 billing unit = 10 mg
1,800 mg dose → 180 billing units
J9144 · daratumumab and hyaluronidase-fihj
1,800 mg/30,000 units single-dose vial · JZ on every claim
Calculate this patient's units ↓1,800 mg subcutaneously into the abdomen over 3 to 5 minutes · the same dose on every regimen -- only the interval between doses changes
Darzalex Faspro · 200 billing units carry straight into the claim.
Claim Check builds the whole visit — J9144 units, the administration line, the modifiers and the Medicare allowed amount — and prices it against your payer's rate. The estimate turns the same visit into what the patient owes.
Free · No credit card · No sales call
Patient owes, 1800 mg
Change the payer and the estimate re-prices against that payer's own published rate. The result is a good faith estimate for the patient.
Darzalex Faspro J9144 is billed in units of 10 mg: ordered dose ÷ 10 mg = billing units. The labeled dose is a flat 1,800 mg for every regimen and every indication, so the calculation has no per-kilogram multiplication and nothing to round -- 1,800 mg ÷ 10 mg = 180 billing units, every time.
Darzalex Faspro ships as a 1,800 mg daratumumab / 30,000-unit hyaluronidase-fihj single-dose vial in 15 mL, sized to match the labeled dose exactly, so the amount drawn (1,800 mg) equals the amount administered (1,800 mg) with nothing left over. That is why JZ (no drug discarded) is the modifier on every Darzalex Faspro claim -- unlike a multi-dose-vial drug, there is no per-vial waste math to do.
Medicare pays $57.973 per 10 mg (ASP+6%), effective for claims in Q4 2026 — $10,435.14
for the 180-unit dose above.
| Product | HCPCS | Dose | Billing units |
|---|---|---|---|
| Darzalex Faspro (subcutaneous) | J9144 | 1,800 mg | 180 |
| Darzalex (IV, 16 mg/kg at 80 kg) | J9145 | 1,280 mg | 128 |
IV Darzalex doses by weight (16 mg/kg), so its unit count moves with the patient; Darzalex Faspro's 1,800 mg dose is fixed regardless of weight. Both bill 10 mg per unit on their own code -- shown here for unit basis, not as a substitution: the two are different formulations of the same molecule, billed under different HCPCS codes and different administration codes.
JZ — no discarded drug from the single-dose vial. JW — discarded drug, reported on its own claim line. One of the two is required on every J9144 claim per CMS's July 1, 2023 single-dose container policy.
J9144 × 180 JZ · 96401 × 1. This is the case on every Darzalex Faspro claim,
because the labeled dose is the same 1,800 mg on every regimen and the single-dose vial is sized to match it
exactly.
There is no JW scenario for this product on label: every regimen doses the same 1,800 mg, so the drawn amount and the administered amount are always identical. JW would only arise if a claim documented less than the full vial administered -- a dose reduction or a discontinued injection -- which the label does not describe for any indication.
Darzalex Faspro is injected subcutaneously into the abdomen over 3 to 5 minutes, billed with
96401 (chemotherapy administration, subcutaneous or intramuscular, non-hormonal anti-neoplastic),
which pays $71.81. 96413 and 96415 (chemotherapy infusion administration) never apply
to J9144 -- those codes belong to the infused product, Darzalex (J9145), which runs over 3 to 7 hours.
Pre-medication is required 1 to 3 hours before every dose -- acetaminophen, an antihistamine such as diphenhydramine, and a corticosteroid -- plus a post-injection corticosteroid per the label. Bill each on its own claim line under its own code; this reference does not assign codes to the pre-medications themselves.
96401 is the only administration code this reference uses for Darzalex Faspro. There is no initial-hour or additional-hour split to report, because the injection is not an infusion -- the entire visit runs a few minutes, not hours.
Darzalex Faspro has nine labeled regimens across multiple myeloma and light chain (AL) amyloidosis, and every one of them doses the same 1,800 mg. What changes between regimens is the calendar between doses -- the claim line never does.
J9144 × 180 JZ · 96401 × 1
| Regimen | Schedule | Units per visit |
|---|---|---|
| 4-week regimens & monotherapy | Weekly × 8, every 2 weeks × 8, then every 4 weeks | 180 |
| VMP (6-week cycle) | Weekly × 6, every 3 weeks × 16, then every 4 weeks | 180 |
| VTd/VRd (around transplant) | Weekly × 8, every 2 weeks × 4, transplant, every 2 weeks × 4 | 180 |
| 3-week regimens | Weekly, then every 3 weeks to week 24, then every 4 weeks | 180 |
| High-risk smoldering myeloma | Weekly × 8, every 2 weeks × 8, then every 4 weeks, capped at 39 cycles | 180 |
| AL amyloidosis (D-VCd) | Weekly × 8, every 2 weeks × 8, then every 4 weeks, capped at 2 years | 180 |
Confirm the regimen before the first claim -- the schedule differs by indication and by combination drug, but the dose, the vial and the units never do.
Darzalex Faspro is supplied as a 1,800 mg daratumumab and 30,000 units hyaluronidase-fihj single-dose vial in 15 mL (120 mg/mL) — there is no other size. NDC 57894-503-01, Janssen Biotech. See the FDA-approved Darzalex Faspro prescribing information (BLA 761145) for the full dosing and administration table.
J9144 is the subcutaneous daratumumab-and-hyaluronidase code. The IV form of the same molecule, Darzalex, bills under a separate code, J9145, dosed by weight (16 mg/kg) instead of flat, and administered by infusion (96413 or 96415) instead of injection (96401).
See the HCPCS hub for coding across the family. The Medicare rate for every quarter is on the cost page →
180 billing units. Darzalex Faspro J9144 bills 1 unit per 10 mg, so the 1,800 mg labeled dose is always 180 units.
J9144. The IV form of the same molecule, Darzalex, bills under a different code, J9145, at a weight-based dose instead of a flat one, so the two are never interchangeable on a claim.
JZ on every claim. The 1,800 mg dose exactly fills the single-dose 1,800 mg vial on every regimen, so nothing is left over to discard — there is no JW scenario for this product on label.
96401, always. Darzalex Faspro is a subcutaneous injection, not an infusion, so 96413 and 96415 never apply — those codes belong to the IV product, Darzalex (J9145).
Yes, on their own claim lines. The label requires acetaminophen, an antihistamine and a corticosteroid 1 to 3 hours before every dose, plus a post-injection corticosteroid — each billed under its own code, separate from the J9144 drug line and the 96401 administration line.
$57.973 per 10 mg (ASP+6%), effective for claims in Q4 2026 — $10,435.14 for the standard 1,800 mg (180-unit) dose.
Data current: pricing Q4 2026
Sources: CMS ASP pricing files (Q4 2026); Medicare physician fee schedule (96401, national non-facility); FDA-approved prescribing information (Darzalex Faspro label, Janssen Biotech, BLA 761145, Revised 1/2026); CMS single-dose container JW/JZ policy (effective July 1, 2023); CPT codebook administration-code guidance.
Reviewed September 19, 2026 by Erin Rose, CareCost Estimate founder. Methodology →